US FDA approves a high-strength formulation of Actelion's Ventavis
This article was originally published in Scrip
Executive Summary
The US FDA has approved a new 20mg/ml formulation of Actelion's inhaled prostacyclin analogue, Ventavis (Iloprost), for the treatment of pulmonary arterial hypertension.